Immunosuppression
6
Pipeline Programs
4
Companies
5
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
5
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
2100%
+ 4 programs with unclassified modality
On Market (1)
Approved therapies currently available
Competitive Landscape
4 companies ranked by most advanced pipeline stage
AstellasChina - Shenyang
3 programs2
Once Daily TacrolimusPhase 41 trial
TacrolimusPhase 41 trial
The Differential Effects of 3 Different ImmunosuppressiveN/A1 trial
Active Trials
SandozAustria - Kundl
1 program1
Hydroxychloroquine Sulfate Tablets, 200 mgPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AstellasOnce Daily Tacrolimus
AbbottVirosomal influenza vaccine
AstellasTacrolimus
SandozHydroxychloroquine Sulfate Tablets, 200 mg
AstellasThe Differential Effects of 3 Different Immunosuppressive
Clinical Trials (5)
Total enrollment: 502 patients across 5 trials
Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk
Start: Oct 2012Est. completion: Dec 201736 patients
Phase 4Completed
Influenza Vaccination in Immunocompromized Patients
Start: Oct 2005Est. completion: Mar 2008304 patients
Phase 4Completed
Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients
Start: Apr 2004Est. completion: Dec 2009150 patients
Phase 4Completed
To Demonstrate the Relative Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets
Start: Jul 1993Est. completion: Dec 1993
Phase 1Completed
The Differential Effects of 3 Different Immunosuppressive
Start: Jul 2008Est. completion: Jan 201012 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space